A Higher Antibody Response Is Generated With a 6- to 7-Week (vs Standard) Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Dosing Interval

Author:

Grunau Brian123ORCID,Asamoah-Boaheng Michael24,Lavoie Pascal M5,Karim Mohammad Ehsanul16,Kirkham Tracy L78,Demers Paul A678,Barakauskas Vilte9,Marquez Ana Citlali910,Jassem Agatha N910,O’Brien Sheila F11,Drews Steven J1112,Haig Scott3,Cheskes Sheldon13,Goldfarb David M9

Affiliation:

1. Centre for Health Evaluation & Outcome Sciences, University of British Columbia, Canada

2. Department of Emergency Medicine, University of British Columbia, Canada

3. British Columbia Emergency Health Services, British Columbia, Canada

4. Faculty of Medicine, Clinical Epidemiology, Memorial University of Newfoundland, Canada

5. Department of Pediatrics, University of British Columbia, Canada

6. School of Population and Public Health, University of British Columbia, Canada

7. Dalla Lana School of Public Health, University of Toronto, Toronto, Canada

8. Ontario Occupational Cancer Research Centre, Ontario, Canada

9. Department of Pathology and Laboratory Medicine, University of British Columbia, Canada

10. Public Health Laboratory, British Columbia Centre for Disease Control, British Columbia, Canada

11. Canadian, Blood Services  Canada

12. Laboratory Medicine and Pathology, University of Alberta, Alberta, Canadaand

13. Li Ka Shing Knowledge Institute and Division of Emergency Medicine, Department of Family and Community Medicine, University of Toronto, Ontario, Canada

Abstract

Abstract The optimal dosing interval for severe acute respiratory syndrome coronavirus 2 vaccines remains controversial. In this prospective study, we compared serology results of paramedics vaccinated with mRNA vaccines at the recommended short (17–28 days) vs long (42–49 days) interval. We found that a long dosing interval resulted in higher spike, receptor binding domain, and spike N terminal domain antibody concentrations.

Funder

Government of Canada

Michael Smith Foundation for Health Research

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3